Abstract:Neurodegenerative diseases are characterized by extensive loss of function or death of brain cells, hampering the life quality of patients. Brain-targeted drug delivery is challenging, with a low success rate this far. Therefore, the application of targeting ligands in drug vehicles, such as lipid-based and polymeric nanoparticles, holds the promise to overcome the blood-brain barrier (BBB) and direct therapies to the brain, in addition to protect their cargo from degradation and metabolization. In this review, we discuss the barriers to brain delivery and the different types of brain-targeting ligands currently in use in brain-targeted nanoparticles, such as peptides, proteins, aptamers, small molecules, and antibodies. Moreover, we present a detailed review of the different targeting ligands used to direct nanoparticles to specific brain cells, like neurons (C4-3 aptamer, neurotensin, Tet-1, RVG, and IKRG peptides), astrocytes (Aquaporin-4, D4, and Bradykinin B2 antibodies), oligodendrocytes (NG-2 antibody and the biotinylated DNA aptamer conjugated to a streptavidin core Myaptavin-3064), microglia (CD11b antibody), neural stem cells (QTRFLLH, VPTQSSG, and NFL-TBS.40–63 peptides), and to endothelial cells of the BBB (transferrin and insulin proteins, and choline). Reports demonstrated enhanced brain-targeted delivery with improved transport to the specific cell type targeted with the conjugation of these ligands to nanoparticles. Hence, this strategy allows the implementation of high-precision medicine, with reduced side effects or unwanted therapy clearance from the body. Nevertheless, the accumulation of some of these nanoparticles in peripheral organs has been reported indicating that there are still factors to be improved to achieve higher levels of brain targeting. This review is a collection of studies exploring targeting ligands for the delivery of nanoparticles to the brain and we highlight the advantages and limitations of this type of approach in precision therapies.

Targeting the transferrin receptor for brain drug delivery

Blood-Brain Barrier Transport of Transferrin Receptor-Targeted Nanoparticles

Transferrin-conjugated, fluorescein-loaded magnetic nanoparticles for targeted delivery across the blood–brain barrier

Transferrin receptor 1 targeted nanomedicine for brain tumor therapy

Receptor-mediated therapeutic transport across the blood–brain barrier

Targeted transport of biotherapeutics at the blood-brain barrier

Smart Strategies for Therapeutic Agent Delivery into Brain across the Blood-Brain Barrier Using Receptor-Mediated Transcytosis

Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody

Receptor-Assisted Nanotherapeutics for Overcoming the Blood–Brain Barrier

Apicobasal transferrin receptor localization and trafficking in brain capillary endothelial cells

Research Progress in Brain-Targeting Drug Delivery Systems

Perspectives on Brain-Targeting Drug Delivery Systems.

Brain-targeted drug delivery - nanovesicles directed to specific brain cells by brain-targeting ligands

Transport of nanomedicines across the blood-brain barrier: Challenges and opportunities for imaging and therapy

Development of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier

Brain-targeted nanoparticle drug delivery systems:research advances

Influence factors on and potential strategies to amplify receptor-mediated nanodrug delivery across the blood–brain barrier

Blood–brain barrier transporters: a translational consideration for CNS delivery of neurotherapeutics

Utilizing Multifaceted Approaches to Target Drug Delivery in the Brain: From Nanoparticles to Biological Therapies

Transferrin Receptor-Targeted Nanocarriers: Overcoming Barriers to Treat Glioblastoma

Research Advances in Brain-Targeted Nanoscale Drug Delivery System